Hard Right Into Phase 3

The current stack was working fine until a fresh triple-agonist readout dropped at 2 a.m.

Filed under Retatrutide ·Survodutide ·Cagrilintide · #stack-life ·#glp-1 ·#cope

Active Compounds

Retatrutide · Triple GIP/GLP-1/Glucagon Receptor Agonist

An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

Cagrilintide · Amylin Analogue

A long-acting amylin analogue being developed in combination with semaglutide (CagriSema) for enhanced weight loss.

RX: Retatrutide · Survodutide · Cagrilintide
Dosage: one fresh readout
Half-life: until the next preprint
Source: manual
Tags: stack-life , glp-1 , cope
Stamped: 2026-05-30 · Cycle 022
Lot #: LOT-20260530T15:33:15.828Z